Clomid is an Ovulation Stimulator. It induces ovulation by stimulating the release of pituitary gonadotropins.

**Pre-Authorization Criteria:**

- treatment of ovulatory failure in patients desiring pregnancy. VCHCP requires that:
  - Doses in excess of 150mg daily for 5 days be prescribed by a fertility specialist.
  - Doses up to 150mg daily for 5 days **may** be prescribed by a family practitioner who has experience treating infertility

**DOSING: ADULTS**

Infertility (in males): Oral: 25 mg/day for 25 days with 5 days rest, or 100 mg every Monday, Wednesday, Friday

Ovulatory failure (females): Oral: 50 mg/day for 5 days (first course); start the regimen on or about the fifth day of cycle. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg Clomid®. A low dosage or duration of treatment course is particularly recommended if unusual sensitivity to pituitary gonadotropin is suspected, such as in patients with polycystic ovary syndrome.

Repeat dosing: If ovulation does not appear to occur after the first course of therapy, a second course of 100 mg/day (two 50 mg tablets given as a single daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one after precautions are taken to exclude the presence of pregnancy. Increasing the dosage or duration of therapy beyond 100 mg/day for 5 days is not recommended. The majority of patients who are going to ovulate will do so after the first course of therapy. If ovulation does not occur after 3 courses of therapy, further treatment is not recommended and the patient should be re-evaluated. If 3 ovulatory responses occur, but pregnancy has not been achieved, further treatment is not recommended. If menses does not occur after an
ovulatory response, the patient should be re-evaluated. Long-term cyclic therapy is not recommended beyond a total of about 6 cycles.

**DOSING: ELDERLY - Refer to adult dosing.**

**DOSAGE FORMS - Tablet, as citrate: 50 mg**

**CONTRAINDICATIONS -** Hypersensitivity to clomiphene citrate or any of its components; liver disease; abnormal uterine bleeding; enlargement or development of ovarian cyst; uncontrolled thyroid or adrenal dysfunction in the presence of an organic intracranial lesion such as pituitary tumor; pregnancy

**WARNINGS / PRECAUTIONS -** Patients unusually sensitive to pituitary gonadotropins (eg, polycystic ovary disease); multiple pregnancies, blurring or other visual symptoms can occur, ovarian hyperstimulation syndrome, and abdominal pain

**PREGNANCY RISK FACTOR - X**

**LACTATION -** Excretion in breast milk unknown/contraindicated

**PATIENT EDUCATION -** May cause visual disturbances, dizziness, lightheadedness. If possibility of pregnancy, stop the drug and consult your prescriber.

**REFERENCES**

Select Drug Information from Lexi-Comp Online <http://www.lexi.com/web/partpage.jsp?id=100002>™

Copyright (1978 to present) Lexi-Comp, Inc.

©2013 UpToDate® www.uptodate.com

Epocrates 2013 - www.epocrates.com

**Revision History:**

Date Reviewed/Updated: 10/17/11 by A. Reeves MD
Date Reviewed/No Updates: 4/2/12; 1/16/13 by A. Reeves MD
Date Approved by P&T Committee: 7/28/05; 10/25/11; 4/24/12; 1/29/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>